Pregled bibliografske jedinice broj: 1104000
Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)
Prognostic value of circulating Bcl-2 and anti- p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years) // Cancer Biomarkers, 22 (2020), 1-10 doi:10.3233/cbm-201497 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1104000 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Prognostic value of circulating Bcl-2 and anti-
p53 antibodies in patients with breast cancer:
A long term follow-up (17.5 years)
Autori
Sirotković-Skerlev, Maja ; Dedić Plavetić, Natalija ; Sedlić, Filip ; Kuna, Sanja Kusačić ; Vrbanec, Damir ; Belev, Borislav ; Pleština, Stjepko ; Kovač, Zdenko ; Kulić, Ana
Izvornik
Cancer Biomarkers (1574-0153) 22
(2020);
1-10
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Bcl-2 ; Breast cancer ; ELISA ; anti-p53 antibodies ; survival
Sažetak
Background: Apoptosis inhibition is a major tumorigenic factor. Bcl-2 dysregulation and TP53 mutation status, which may correlate with autoantibody generation, contribute to impaired apoptosis. Objective: This study aimed to investigate the prognostic value of circulating Bcl-2 and anti- p53 antibodies (p53Abs) in a 17.5- year follow- up of breast cancer patients. We also analyzed the correlations of Bcl-2 and p53Abs with various clinicopathological parameters in order to assess their impact on tumor aggressiveness. Methods: Serum Bcl-2 and p53Abs levels were analyzed by the enzyme- linked immunosorbent assay (ELISA) in 82 patients with invasive breast cancer and twenty individuals without malignancy. Results: Serum Bcl-2 and p53Abs levels in breast cancer patients were significantly higher than those in controls. Patients with high levels of Bcl-2 (cut-off 200 U/ml) had a poorer prognosis (17.5-year survival) than those with lower Bcl- 2 values. In combined analysis the subgroup of patients with elevated p53Abs (cut-off 15 U/ml) and elevated Bcl-2 (cut-offs 124 U/ml and 200 U/ml) had the worse prognosis in 17.5-year survival. In correlation analysis p53Abs and Bcl-2 were associated with unfavorable clinicopathological parameters. Conclusions: Our results suggest that breast cancer patients with high serum levels of p53Abs and Bcl-2 present an especially unfavorable group in a long follow-up.
Izvorni jezik
Engleski
Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Sveučilište Jurja Dobrile u Puli
Profili:
Zdenko Kovač
(autor)
Stjepko Pleština
(autor)
Borislav Belev
(autor)
Ana Kulić
(autor)
Maja Sirotković-Skerlev
(autor)
Filip Sedlić
(autor)
Damir Vrbanec
(autor)
Natalija Dedić-Plavetić
(autor)
Sanja Kusačić Kuna
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE